ArticlePloS one2025
A multicenter study on rates and risk factors of proliferative vitreoretinopathy in a low-income economy.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the rate and identify risk factors for proliferative vitreoretinopathy (PVR) in Nigerian patients with rhegmatogenous retinal detachment (RRD). METHODS AND ANALYSIS: Multicenter, prospective, cross-sectional study of consecutive RRD patients attending four ophthalmic clinics, recruited over a period of twelve months. Biodata, presenting complaints, symptom duration, best corrected visual acuity, extent of RRD, status of macular attachment, presence, and grade of PVR and fellow eye were assessed. Data was analyzed using SPSS version 22 (Pearson Chi-Square test, Mann-Whitney U test, Fisher's Exact test, and logistic regression analysis).
results154 of 174 eyes with RRD were included in the final analysis, and 53/154 (34.4%) developed PVR. Twenty eyes (11.5%) had media opacity, and detailed retinal examination was not possible (diagnosed via B-scan ultrasound). 154 RRD was analyzed. Therefore, the rate of all PVR was53/154 (34.4%). Grades of PVR: Grade D: 27 eyes (50.9%), Grade C: 19 eyes (35.9%), Grade B: 5 eyes (9.4%), and Grade A: 2 eyes (3.8%). The rate of advanced PVR grades D + C is 46/154 (29.8%). Forty-six of 53 PVR eyes (86.6%) had vision 3/60 or less (p < 0.001). Risk factors associated with PVR were extremes of age, i.e., < 25 and >66 years (especially older age (>66 years)), previous intraocular surgery, longer symptom duration, and RD features including 4-quadrant involvement, total RD, macular involvement by RD, and presence of fellow eye RD. Gender, Myopia, and trauma were not risks for PVR.
conclusionPrevious reports of PVR rates in Nigerians may have been underestimated. A multi-pronged approach, including research into adjuvant pharmacotherapy, can reduce PVR rates and improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.